Navigation Links
Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
Date:7/9/2008

Renowned oncology researcher Dr. Daniel Von Hoff, a member of President Bush's National Cancer Advisory Board, provides an in-depth look at "The Complete Phase Ib," an oncology clinical trial design that creates rapid accrual rates, substantial economies of scale, significant time savings, enthusiasm from investigators and patients, and improved therapeutic benefits. The complete interview is available for download from Medelis, a contract research organization providing complete oncology clinical trial design, management and execution.

Phoenix, AZ (PRWEB) July 9, 2008 -- Medelis, Inc., a contract research organization providing complete oncology clinical trial design, management and execution, today published a free new downloadable abstract, "The Complete Phase Ib: An Approach to Getting to Phase II Faster", an interview with renowned oncology investigator Daniel Von Hoff, M.D.

In the interview, Dr. Von Hoff discusses "The Complete Phase Ib", a trial design that streamlines phase I by testing various drug combinations in one trial with multiple arms running in parallel. This structure creates rapid accrual rates, substantial economies of scale and significant time savings for sponsors versus the traditional sequential approach. It also garners enthusiasm from investigators and patients, who ultimately gain greater potential for improved therapeutic benefits and care.

Dr. Von Hoff provides insight and details on a variety of questions about this approach:

  • The phase Ib concept
  • Patient accrual and treatment benefits
  • How the approach can "rescue" patients
  • Dosing strategies
  • Logistical considerations
  • Cost and timing considerations
  • Effects on phase II studies
  • Reactions from the FDA, investigators, sponsors and patients

A member of President Bush's National Cancer Advisory Board, Dr. Von Hoff's major interest is in the development of new anticancer agents both in the clinic and in the laboratory. His laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies with a focus on pancreatic cancer.

Dr. Von Hoff currently serves as Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He also serves as Chief Scientific Officer for U.S. Oncology and the Scottsdale Clinical Research Institute and is a founding shareholder and advisory board member of Medelis.

The abstract is the second in Medelis' complimentary "Peer Perspectives in Oncology" Q&A series, which brings together respected researchers to discuss issues that face Chief Medical Officers today: rising costs, optimum patient accrual, targeted therapeutics, patient safety, FDA regulations, efficacy, budgets, and timelines.

The abstract is available for download in the Insider Abstracts section of Medelis' Web site.

About Medelis, Inc.:
Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, clinical trial management physicians and advisory board members, including Dan Von Hoff, James Gourzis, Howard Burris and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Offerings include strategic plans for regulatory approval from phase I through NDA and complete oncology clinical trial design, management and execution.

Medelis is privately-held and located in Phoenix, Arizona with locations in Nashville, Phoenix and Reno.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
2. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
3. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
4. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
7. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
8. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
9. Derma Sciences CEO ED Quilty Discusses Company on BNN
10. PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors
11. PAHEF Discusses Neglected Diseases and Disaster Preparedness with Innovative Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added the medical group ... professionals working on a personal injury lien basis. Founded by Dr. Wayne Cheng, MD ... doctors’ vast experience with orthopedic injuries to patients in the Inland Empire. , Bones ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The ... unveiled a redesigned website. The new site – still located at http://www.garlandco.com ... contractors and other industry users that Garland serves. , After an ambitious phase ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on one ... better one’s life through God. “The Trials I Face to Receive God’s Grace” is ... found a love for writing. Green feels that expressing his feelings through prayer will ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the inspirational ... to God. “Psalms of Humidity” is the creation of published author, David Waldrop, an ... life are the very same things that have shaped him into the man that ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
(Date:8/31/2017)... NEW YORK , Aug. 31, 2017 ... the industry,s must-read guide to the latest innovations happening ... the first industry publication to focus on providing a ... advancements. Ultimately, the issue covers the most innovative companies, ... year. "Everyone in ...
Breaking Medicine Technology: